Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
A phase 1/2 trial of OSE2101 in non-small-cell lung cancer and small-cell lung cancer, run by OSE Immunotherapeutics, now recruiting.
Overview
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05751798 by OSE Immunotherapeutics, with 41 participants planned, started 2022-12-20 and due to reach its primary completion in 2029-12. Interventions recorded: Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg, Part B: OSE-279 600 mg and OSE2101, Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive. Conditions listed: Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.